5 Best Immunology Stocks to Buy According to Hedge Funds

2. Merck & Co., Inc. (NYSE:MRK)

Number of Hedge Fund Holders: 98

Merck & Co., Inc. (NYSE:MRK) is also one of the best immunology stocks to buy.

TheFly reported on May 22 that MRK announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive recommendation supporting approval of KEYTRUDA in combination with Padcev for adults with resectable muscle-invasive bladder cancer who are not eligible for cisplatin-based chemotherapy. The CHMP opinion covers the use of KEYTRUDA, including its subcutaneous formulation, in the perioperative setting, with treatment continued after radical cystectomy.

The recommendation will now be reviewed by the European Commission, with a final decision expected in the third quarter of 2026. The decision is supported by Phase 3 KEYNOTE-905 results showing meaningful improvements in event-free survival, overall survival, and pathologic complete response compared with surgery alone.

Concurrently, on May 18, Merck & Co., Inc. (NYSE:MRK) reported that its Phase 3 TroFuse-005 study of sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate developed with Kelun-Biotech, achieved both of its primary endpoints. The trial demonstrated statistically significant improvements in overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer who had previously received platinum-based chemotherapy and anti–PD-1/PD-L1 therapy.

It also met a key secondary endpoint of objective response rate. These results represent the first global Phase 3 evidence showing superiority over chemotherapy in this setting and will be shared at a future medical meeting. Merck stated the safety profile remained consistent with prior studies, with no new safety concerns identified.

Merck & Co., Inc. (NYSE:MRK) is a global biopharmaceutical company with a strong focus on oncology, led by its flagship drug Keytruda. It is also expanding into immunology, developing treatments for immune-mediated inflammatory diseases.